Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE OF REVIEW: Continuing progress in the field of antiganglioside antibodies is expanding our comprehension of the pathogenesis of the inflammatory neuropathies. Recent studies have helped unravel all aspects of this process, addressing a range of subjects from the bacterial and host factors involved in antibody induction through to their pathogenic effects. RECENT FINDINGS: This review focuses on developments in the field over the past 18 months. Advances in our understanding of antibody induction, host risk factors, and pathogenic end effects are described systematically, and particular attention is given to the novel concept of ganglioside complexes. SUMMARY: The wealth of scientific data is now driving the design of novel, targeted therapies. This preclinical research is outlined and suggestions made as to how this might be translated into clinical practice.

Original publication




Journal article


Curr Opin Neurol

Publication Date





540 - 546


Animals, Antibodies, Carbohydrate Sequence, Gangliosides, Humans, Molecular Sequence Data, Peripheral Nervous System Diseases, Risk Factors